The U.S. Food and Drug Administration has declared a shortage of Eli Lilly’s Mounjaro, the latest diabetes drug to be in short supply.
Due to increased demand for the medication, pharmacies may experience delays in receiving full shipments of the 5-milligram dose through January, according to a posting this week on the regulator’s website.
The FDA site says other doses are still available at this time, but the University of Utah drug information service – which tracks shortages through reports from pharmacies and providers – says the 2.5- and 7.5-milligram doses are also on intermittent backorder.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
